▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 28, 2024

Bio

Celltrion chief to attend marketing unit’s roadshow

  • PUBLISHED :June 09, 2017 - 17:49
  • UPDATED :June 09, 2017 - 17:49
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Celltrion founder and chairman Seo Jung-jin will attend an investor roadshow next month ahead of the planned initial public offering of its marketing unit Celltrion Healthcare, the company confirmed on June 9.

“The chairman will preside over the roadshow to give clear answers to questions raised by investors,” Celltrion Healthcare spokesperson Lee Han-ki told The Investor.




Starting from July 3, Celltrion Healthcare will launch an investor roadshow traveling to New York, San Francisco, London, Hong Kong and Singapore for two weeks.

The company official, however, declined to confirm whether the chairman will visit all the cities, saying the travel schedule has not yet been finalized.

Celltrion Healthcare, which owns the exclusive rights to market, sell and distribute Celltrion’s biosimilar drugs, aims to raise up to 1 trillion won (US$890 million) from its planned listing on the nation’s secondary KOSDAQ next month.

It will sell 24,604,000 new shares at an indicative price range of 32,500 won to 41,000 won.

The company’s stock listing faced uphill battle when the original plans for September last year were pushed back due to accounting woes following its profit overstatement.

Investors also have been questioning why Celltrion Healthcare, which was an in-house sales unit of Celltrion, was spun off as a separate firm in 2010.

During a roadshow in March this year, Seo said Celltrion was “burdened to take risks alone having to continue research and development at the time of the spin-off.”

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS